Everest Organics Limited manufactures and sells pharmaceutical products in India.
+ 1 more risk
Solid track record with adequate balance sheet.
Share Price & News
How has Everest Organics's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: 524790's share price has been volatile over the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: 524790 underperformed the Indian Pharmaceuticals industry which returned -0.4% over the past year.
Return vs Market: 524790 underperformed the Indian Market which returned 6.4% over the past year.
Price Volatility Vs. Market
How volatile is Everest Organics's share price compared to the market and industry in the last 5 years?
Simply Wall St News
Is Everest Organics undervalued compared to its fair value and its price relative to the market?
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: 524790 (₹128) is trading above our estimate of fair value (₹61.75)
Significantly Below Fair Value: 524790 is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: 524790 is good value based on its PE Ratio (13x) compared to the Pharmaceuticals industry average (16.3x).
PE vs Market: 524790 is good value based on its PE Ratio (13x) compared to the Indian market (13x).
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate 524790's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: 524790 is overvalued based on its PB Ratio (3.4x) compared to the IN Pharmaceuticals industry average (1.5x).
How is Everest Organics forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Everest Organics has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
- Check out Everest Organics's track record over time to understand how much the company has returned to shareholders and its earnings growth rate in the past.
- Everest Organics competitive advantages and company strategy can generally be found in its financial reports archived here.
- Explore growth companies in the Pharmaceuticals & Biotech industry.
How has Everest Organics performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 524790 has high quality earnings.
Growing Profit Margin: 524790's current net profit margins (4.5%) are higher than last year (4.5%).
Past Earnings Growth Analysis
Earnings Trend: 524790's earnings have grown significantly by 53.1% per year over the past 5 years.
Accelerating Growth: 524790's earnings growth over the past year (29.7%) is below its 5-year average (53.1% per year).
Earnings vs Industry: 524790 earnings growth over the past year (29.7%) exceeded the Pharmaceuticals industry 22%.
Return on Equity
High ROE: 524790's Return on Equity (26.2%) is considered high.
Return on Assets
Return on Capital Employed
How is Everest Organics's financial position?
Financial Position Analysis
Short Term Liabilities: 524790's short term assets (₹711.1M) do not cover its short term liabilities (₹727.7M).
Long Term Liabilities: 524790's short term assets (₹711.1M) exceed its long term liabilities (₹111.6M).
Debt to Equity History and Analysis
Debt Level: 524790's debt to equity ratio (74%) is considered high.
Reducing Debt: 524790's debt to equity ratio has reduced from 448.7% to 74% over the past 5 years.
Debt Coverage: 524790's debt is well covered by operating cash flow (49.5%).
Interest Coverage: 524790's interest payments on its debt are well covered by EBIT (8.9x coverage).
Inventory Level: 524790 has a high level of physical assets or inventory.
Debt Coverage by Assets: 524790's debt is covered by short term assets (assets are 3.2x debt).
What is Everest Organics's current dividend yield, its reliability and sustainability?
Current Dividend Yield
Dividend Yield vs Market
Current dividend yield vs market & industry
Notable Dividend: 524790's dividend (0.78%) is higher than the bottom 25% of dividend payers in the Indian market (0.6%).
High Dividend: 524790's dividend (0.78%) is low compared to the top 25% of dividend payers in the Indian market (2.63%).
Stability and Growth of Payments
Stable Dividend: Too early to tell whether 524790's dividend payments have been stable as they only just started paying a dividend.
Growing Dividend: Too early to tell if 524790's dividend payments are increasing as they only just started paying a dividend.
Current Payout to Shareholders
Dividend Coverage: With its low payout ratio (10.1%), 524790's dividend payments are thoroughly covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: Insufficient data to determine if a dividend will be paid in 3 years and that it will be covered by earnings.
How experienced are the management team and are they aligned to shareholders interests?
Average board tenure
Srikakarlapudi Raju (67yo)
Dr. Srikakarlapudi Srihari Raju serves as the Managing Director since January 1, 2016 and Executive Director at Everest Organics and served as its Compliance Officer.
CEO Compensation Analysis
Compensation vs Market: Srikakarlapudi's total compensation ($USD41.77K) is about average for companies of similar size in the Indian market ($USD49.94K).
Compensation vs Earnings: Srikakarlapudi's compensation has been consistent with company performance over the past year.
|MD & Executive Director||4.1yrs||₹3.00m||19.43% ₹192.0m|
|Technical Director & Executive Director||15.5yrs||₹1.80m||0.00045% ₹4.4k|
|Whole Time Director||12.4yrs||₹900.00k||0.47% ₹4.7m|
|Non-Executive Director||24.8yrs||₹10.00k||1.42% ₹14.0m|
|Independent Non Executive Director||10.4yrs||₹70.00k||no data|
|Independent Chairman||0yrs||₹70.00k||0.0090% ₹89.0k|
|Non-Executive Director||5.6yrs||₹30.00k||1.35% ₹13.3m|
|Independent Director||5.6yrs||₹50.00k||no data|
Experienced Board: 524790's board of directors are seasoned and experienced ( 12.4 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 50.7%.
Everest Organics Limited's company bio, employee growth, exchange listings and data sources
- Name: Everest Organics Limited
- Ticker: 524790
- Exchange: BSE
- Founded: 1993
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: ₹988.400m
- Shares outstanding: 8.00m
- Website: https://www.everestorganicsltd.com
Number of Employees
- Everest Organics Limited
- Lakeview Plaza
- 1st Floor, Plot No.127 & 128
- Andhra Pradesh
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|524790||BSE (Mumbai Stock Exchange)||Yes||Equity Shares||IN||INR||Mar 2001|
Everest Organics Limited manufactures and sells pharmaceutical products in India. It offers active pharmaceutical ingredients and intermediaries. The company also exports its products to Europe, the United States, the Far East and the Middle East, and Latin/Central/South American Countries. Everest Organics Limited was incorporated in 1993 and is based in Hyderabad, India.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/02/26 12:41|
|End of Day Share Price||2020/02/26 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.